VERVE THERAPEUTICS INC. - COMMON STOCK

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

14 أبريل 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

11 أبريل 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 أبريل 2025 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

24 مارس 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 مارس 2025 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

27 فبراير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 فبراير 2025 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

29 يناير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

13 يناير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08 يناير 2025 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 يناير 2025 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

29 نوفمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

05 نوفمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2024 15:26:49 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 أكتوبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 سبتمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results

08 أغسطس 2024 06:00:01 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 أغسطس 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 يوليو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

28 يونيو 2024 06:00:00 بحسب Nasdaq GlobeNewswire